Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain Array invented compounds targeted at the tropomyosin kinase (“Trk”) family of receptors, including LOXO-101. In April 2014 and again in April 2015, Array and Loxo amended the agreement […]

New Haven Pharmaceuticals (New Haven, CT), a specialty pharmaceutical company focused on a slow release aspirin product, closed a $6.6M Series A. Participants include Connecticut Innovations and private investors.

Rib-X Pharmaceuticals (New Haven, CT), a clinical-stage pharmaceutical company developing next-generation antibiotics, closed an $18.7M Series B financing. Participants include Vatera Healthcare Partners, Warburg Pincus, ABS Ventures and Vox Equity Partners.

SurgiQuest (Milford, CT) a commercial-stage medical device company focused on minimally invasive surgery products for access to the abdominal cavity, closed a $19M Series D financing. Participants include River Cities Capital Funds, Fletcher Spaght Ventures, California Technology Ventures and Aphelion Medical Fund. Thanx for your patience as we catch-up.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.

Cara Therapeutics (Shelton, CT) a clinical-stage small molecule company focused on pain and inflammation, closed a $15M Series D financing. Participants include Rho Ventures, Alta Partners, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Mitsubishi International and MVM Life Science Partners.

Kolltan Pharmaceuticals (New Haven, CT) a development-stage biopharmaceutical company focused on monoclonal antibody oncology therapeutics, closed a $8.5M Series B financing. Participants include Celtic Therapeutics Holdings and Tichenor Ventures.

Kolltan Pharmaceuticals (New Haven, CT) an early-stage developer of oncology therapeutics leveraging the receptor tyrosine kinase targets closed a $5M Series A, bring the total financing round to $40M. Participants include Purdue Pharma, HBM Bioventures, the Pritzker family and Diaz and Altschul Capital Management.

Marinus Pharmaceuticals (Branford, CT) a clinical-stage company focused on reformulation and development of therapeutics for the treatment of CNS, psychiatric and pain disorders, closed a $20M Series B financing. Participants include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $25M Series D financing. Participants include Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Kolltan Pharmaceuticals (New Haven, CT) an early-stage developer of oncology therapeutics leveraging the receptor tyrosine kinase targets closed a $35M Series A financing. Participants include Purdue Pharma, HBM Bioventures, the Pritzker family and Diaz and Altschul Capital Management.

  

to top of page...